Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Gynecologic 2Breast 2Sarcoma 1Plasma cell 1Gastrointestinal 1

Conditions

Lymphoma 2Vomiting 1Nausea 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Colonic Neoplasms 1Burkitt Lymphoma 1

Interventions

Rituximab 1371Cyclophosphamide 1296Vincristine 662Doxorubicin 583Etoposide 525Prednisone 504Cytarabine 481fludarabine 461Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 254ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 227Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Prochlorperazine × Lymphoid × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT01843868 2024-08-07

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Australasian Leukaemia and Lymphoma Group

Phase NA Withdrawn
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Nausea, Vomiting

NCT01851369 2024-05-08

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
93 enrolled 27 charts
GastrointestinalLymphoid

Colonic Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡